Multidrug resistance reversal in childhood malignancies - Potential for a real step forward?

European Journal of Cancer Part A

Volumn 32, Issue 4, 1996, Pages 641-644

  Pinkerton, C R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CEFOPERAZONE; CEFTRIAXONE; CYCLOSPORIN; DIPYRIDAMOLE; FLUPHENAZINE; MEPACRINE; PROGESTERONE; QUINIDINE; QUININE; TAMOXIFEN; TRIFLUOPERAZINE; VALSPODAR;

ADOLESCENT; CHILD; CHILDHOOD CANCER; DRUG THERAPY; HUMAN; INFANT; MULTIDRUG RESISTANCE; PREVENTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029975129     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00663-X     Document Type: Note

References (37)

1. CR Pinkerton J Pritchard L Spitz High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy J Clin Oncol 4 1986 194 199
2. G Perilongo J Plaschkes J Brown Response of hepatoblastoma (HB) to pre-operative chemotherapy with cisplatin (CPDD) and doxorubicin (Doxo) PLADO in the International Society of Paediatric Oncology (SIOP) Liver Tumour Study 2nd edition Proc Am Soc Clin Oncol 14 1995 444
3. EA Shafford DW Rogers J Pritchard Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26 J Clin Oncol 2 1984 742 747
4. DM Tishler KI Weinberg LS Sender JA Nolta C Raffel Multidrug resistance gene expression in paediatric primitive neuroectodermal tumours of the central nervous system J Neurosurg 76 1992 507 512
5. A Roessner Y Ueda B Bockhorn-Dworniczak Prognostic implication of immunodetection of P glycoprotein in Ewing's sarcoma J Cancer Res Clin Oncol 119 1993 185 189
6. HSL Chan PS Thorner G Haddad V Ling Immunohistochemical detection of P glycoprotein: prognostic correlation in soft tissue sarcoma of childhood J Clin Oncol 8 1990 689 704
7. HSL Chan G Haddad PS Thorner P glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma N Engl J Med 325 1991 1608 1614
8. NA Brophy JP Marie VA Rojas MDR 1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques Leukemia 8 1994 327 335
9. J Bernard J Bourhis F de Vathaire Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis Adv Neuroblastoma Res 4 1994 111 116
10. J Kuttesch D Parham X Luo P glycoprotein (P-gp) expression at diagnosis is not predictive of worse outcome in pediatrie rhabdomyosarcoma (RMS) 2nd edition Proc Am Soc Clin Oncol 13 1994 1409
11. M Favrot V Combaret E Goulot Expression of P glyco-protein restricted to normal cells in neuroblastoma biopsies Br J Cancer 64 1991 233 238
12. B Leyland-Jones W Dalton G Fisher BI Sikic Reversal of multidrug resistance to cancer chemotherapy Cancer 72 1993 3484 3488
13. CF Higgins MM Gottesman Is the multidrug transporter a flippase? Trends Biochem Sci 17 1992 18 21
14. WS Dalton TM Grogan PS Meltzer Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P glycoprotein and potential circumvention by addition of verapamil to chemotherapy J Clin Oncol 7 1989 415 424
15. P Sonneveld BGM Durie HM Lokhorst Modulation of multidrug resistance multiple myeloma by cyclosporin Lancet 340 1992 255 259
16. RJ Motzer P Lyn P Fischer Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma J Clin Oncol 8 1995 1958 1965
17. WH Wilson SE Bates A Fojo Controlled trial of dexvera-pamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy J Clin Oncol 13 1995 1995 2004
18. MS Cairo S Siegel N Anas L. Sender Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug resistant pediatric tumours Cancer Res 49 1989 1063 1066
19. FJ Cowie CR Pinkerton Mti]Continuous-infusion Phillips with etoposide in relapsed or resistant paediatric cancers verapamil Br J Cancer 71 1995 877 881
20. HSL Chan G Koren PS Thorner Reversal of multidrug resistance (MDR) in retinoblastoma (RB) by cyclosporin A (CsA) 2nd edition Proc Am Assoc Clin Oncol ii 1992 375
21. HSL Chan PS Thorner S Weitzman Cyclosporin A for reversal of multidrug resistance in childhood malignancies 2nd edition Proc Am Assoc Cancer Res 33 1992 478
22. RF Ozols RE Cunnion RW Klecker Verapamil and adriamycin in the treatment of drug resistant ovarian cancer patients J Clin Oncol 5 1987 641 647
23. S Salmon WS Dalton TM Grogan Multidrug resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer Blood 78 1991 44 50
24. E Friche PB Jensen NI Nissen Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor Cancer Chemother Pharmacol 30 1992 235 237
25. GA Fisher J Hausdorff BL Lum Phase I trial of etoposide with the cyclosporin SDZ PSC 833, a modulator of multidrug resistance/MDR 2nd edition Proc Am Soc Clin Oncol 13 1994 368
26. GA Fisher J Halsey J Hausdorff A phase I study of paclitaxal in combination with SDZ PSC 833, a potent modulator of multidrug resistance (MDR) Anti-Cancer Drugs 5 1994 43
27. P Sonneveld JP Marie HM Lokhorst K Nooter M Schoester Clinical modulation of multidrug resistance in VAD refractory multiple myeloma: studies with cyclosporin and SDZ PSC833 Anti-Cancer Drugs 5 1994 72
28. HL McLeod Clinical reversal of the multidrug resistance pheno-type: true tumour modulation or pharmacokinetic interaction Eur J Cancer 30 1994 2039 2041
29. M Gigante G Toffoli M Boiocchi Pharmacokinetics of doxorubicin co-administered with high-dose verapamil Br J Cancer 71 1995 134 136
30. NL Bartlett BL Lum GA Fisher Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance J Clin Oncol 12 1994 835 842
31. DA Rushing SR Raber KA Rodvold SC Piscitelli GS Plank DA Tewksbury The effects of cyclosporin on the pharmacokinetics of doxorubicin in patients with small cell lung cancer Cancer 74 1994 834 841
32. AM Yahanda KM Adler GA Fisher Phase I trial of etoposide with cyclopsorin as a modulator of multidrug resistance J Clin Oncol 10 1992 1624 1634
33. JK Horton KN Thimmaiah JA Houghton Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts Biochem Pharmacol 38 1989 1727 1736
34. F Cowie CR Pinkerton Enhanced toxicity of dactinomycin and vincristine by cyclosporin given to reverse multidrug resistance J Clin Oncol 12 1994 1998 1999
35. R Milroy A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer Cancer 68 1993 813 818
36. WS Dalton JJ Crowley SS Salmon A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma Cancer 75 1995 815 820
37. MJ Millward BMJ Cantwell NC Munro A Robinson PA Corris AL Harris Oral verapamil with chemotherapy for advanced non small cell lung cancer: a randomised study Br J Cancer 67 1993 1031 1035